People with impaired memory and increased brain amyloid levels who received verubecestat, especially those who were given larger doses, had higher estimated mean changes on the Clinical Dementia Rating Scale Sum of Boxes between baseline and 104 weeks, suggesting worse outcomes, compared with those who took placebo, according to a study in The New England Journal of Medicine. Another study in the same journal also showed greater reductions in Preclinical Alzheimer's Cognitive Composite scores after six months among those who received atabecestat, particularly those who took higher doses, compared with the placebo group.
Verubecestat, atabecestat don't curb Alzheimer's progression
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.